Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C

• Main Authors: ZHAO Xitai, NIE Qinghe
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2017-06-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=8256

In recent years, direct-acting antiviral agents (DAAs) have achieved great success in the treatment of hepatitis C and have replaced interferon/ribavirin. However, since DAAs were launched not long ago, there lacks sufficient knowledge of their toxic and side effects, interactions with other drugs, and safety in patients complicated by other serious chronic diseases. The results of many large-scale clinical trials show that DAAs have good safety in different populations and serious toxic and side effects are rare, but drug interactions need to be taken seriously. The addition of ribavirin in DAA regimen or prolongation of DAA treatment does not increase patients’ benefits and may cause more adverse events. Moreover, at the same time of DAA treatment, liver injury caused by HCV cannot be neglected, and continuous treatment should be given.